<SEC-DOCUMENT>0001178913-25-001673.txt : 20250509
<SEC-HEADER>0001178913-25-001673.hdr.sgml : 20250509
<ACCEPTANCE-DATETIME>20250509160525
ACCESSION NUMBER:		0001178913-25-001673
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20250509
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250509
DATE AS OF CHANGE:		20250509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Entera Bio Ltd.
		CENTRAL INDEX KEY:			0001638097
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38556
		FILM NUMBER:		25930325

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT HADASSAH, MINRAV BUILDING
		STREET 2:		FIFTH FLOOR
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9112002
		BUSINESS PHONE:		972-2-532-7151

	MAIL ADDRESS:	
		STREET 1:		KIRYAT HADASSAH, MINRAV BUILDING
		STREET 2:		FIFTH FLOOR
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9112002
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>zk2533149.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:entx="http://enterabio.com/20250509" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_e3793fd0246149fc909fd1fcfc95fa89" contextRef="c20250509to20250509" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_2783e5c0c3ef4b5c98066465eeb39ec2" contextRef="c20250509to20250509">0001638097</ix:nonNumeric><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_1fc99da374d94b47827b63bc4df1ea69" contextRef="c20250509to20250509">00-0000000</ix:nonNumeric><ix:nonNumeric name="dei:CityAreaCode" id="Fact_845dc47bf7764f37ae6b3ec21fdb1f1c" contextRef="c20250509to20250509">972</ix:nonNumeric><ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_5b00f5ad8e2a42019f08b2e5b15a63bf" contextRef="c20250509to20250509">2-532-7151</ix:nonNumeric><ix:nonNumeric name="dei:Security12bTitle" id="Fact_33337dadb56448e6803d820203d94d6e" contextRef="c20250509to20250509_StatementClassOfStockAxis_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember">Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary Share</ix:nonNumeric><ix:nonNumeric name="dei:TradingSymbol" id="Fact_a700b67d61a142d989acfd1e03ccdf9c" contextRef="c20250509to20250509_StatementClassOfStockAxis_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember">ENTXW</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_19ac239564e543ae8bdeb253ce77e391" contextRef="c20250509to20250509_StatementClassOfStockAxis_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember">NASDAQ</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_90e9abc973f6425ea56ebe4d147111d6" contextRef="c20250509to20250509_StatementClassOfStockAxis_OrdinarySharesParValueOfNIS00000769Member">NASDAQ</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="entx-20250509.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20250509to20250509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-09</xbrli:startDate><xbrli:endDate>2025-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250509to20250509_StatementClassOfStockAxis_OrdinarySharesParValueOfNIS00000769Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">entx:OrdinarySharesParValueOfNIS00000769Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-09</xbrli:startDate><xbrli:endDate>2025-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250509to20250509_StatementClassOfStockAxis_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">entx:WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-09</xbrli:startDate><xbrli:endDate>2025-05-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
<div style="line-height: initial;">
  <div>
    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>

    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br/>
    </div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Washington, D.C. 20549</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_854b9d1282cb4016850c835312cb7428" contextRef="c20250509to20250509">8-K</ix:nonNumeric></div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">CURRENT REPORT</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_24f7136a7a434d1c8823a066ae74f5f0" contextRef="c20250509to20250509" format="ixt:date-monthname-day-year-en">May 9, 2025</ix:nonNumeric></div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_dc6cd0bdce1a4d91ac30bf2333ad64ce" contextRef="c20250509to20250509">Entera Bio Ltd.</ix:nonNumeric><br/>
    </div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Exact Name of Registrant as Specified in Its Charter)</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 32.01%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_5ccef13b5de64531b55131310f990d6d" contextRef="c20250509to20250509" format="ixt-sec:edgarprovcountryen">Israel</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 2%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 32%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_8531f7f8deb54d378365f039779ae88e" contextRef="c20250509to20250509">001-38556</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 2%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 32%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="-sec-ix-hidden:Fact_1fc99da374d94b47827b63bc4df1ea69">Not Applicable</span><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 32.01%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(State or other jurisdiction<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br/>
              </span>of incorporation)</div>
          </td>

    <td style="width: 2%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 32%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Commission File Number)</div>
          </td>

    <td style="width: 2%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 32%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(I.R.S. Employer<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br/>
              </span>Identification)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_53e7134a8dee464d8f80218269c94f83" contextRef="c20250509to20250509">KIRYAT HADASSAH, MINRAV BUILDING</ix:nonNumeric> &#8211; <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_2921a3eff99c4dd5bff84c01cafc4be3" contextRef="c20250509to20250509">FIFTH FLOOR</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_c317e05c204f4a59a1e4dc8b1f3613c8" contextRef="c20250509to20250509">JERUSALEM</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCountry" id="Fact_5dfe71dfd21e4ab8aee3d679ab8f226a" contextRef="c20250509to20250509" format="ixt-sec:countrynameen">Israel</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_70b738c460a04d3c9513ff7984b36624" contextRef="c20250509to20250509">9112002</ix:nonNumeric></span><br/>
      </span>(Address of principal executive offices) (Zip Code)</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;"><br/>
        <span style="-sec-ix-hidden:Fact_845dc47bf7764f37ae6b3ec21fdb1f1c">+972</span><span style="-sec-ix-hidden:Fact_5b00f5ad8e2a42019f08b2e5b15a63bf">-2-532-7151</span> </span></div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Registrant&#8217;s Telephone Number, Including Area Code)</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;&#160;</div>

    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Former name or former address, if changed since last report)</div>

    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
      under any of the following provisions (see General Instruction A.2. below):</div>

    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">
            <div style="text-align: left; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_aedbad8e66824d61914f676dc82e5ccb" contextRef="c20250509to20250509" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 96.15%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>


</table>
    <div style="line-height: 1.25;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">
            <div style="text-align: left; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_76572359dc7d4cb7bad6d925fd113c86" contextRef="c20250509to20250509" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 96.15%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">
            <div style="text-align: left; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_25c510ae2a4d49a890418808323caadb" contextRef="c20250509to20250509" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 96.15%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</div>
          </td>

  </tr>


</table>
    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">
            <div style="text-align: left; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_095cdde2305a4992902e14b13d9e8daf" contextRef="c20250509to20250509" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 96.15%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))</div>
          </td>

  </tr>


</table>
    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 32.01%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title of each class</div>
          </td>

    <td style="width: 2%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 32%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Trading Symbol(s)</div>
          </td>

    <td style="width: 2%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 32%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name of each exchange on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 32.01%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_ed98f41c93304b78938876a12e4df08c" contextRef="c20250509to20250509_StatementClassOfStockAxis_OrdinarySharesParValueOfNIS00000769Member">Ordinary Shares, par value of NIS 0.0000769</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 2%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 32%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_8f25ca98f88f4f82bc488b6b84f08e53" contextRef="c20250509to20250509_StatementClassOfStockAxis_OrdinarySharesParValueOfNIS00000769Member">ENTX</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 2%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 32%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="-sec-ix-hidden:Fact_90e9abc973f6425ea56ebe4d147111d6">Nasdaq Capital Market</span><br/>
            </div>
          </td>

  </tr>


</table>
    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
      (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_93ab7cbcbd0b4c55bd07e713e802587e" contextRef="c20250509to20250509" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br/>
    </div>

    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
      complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>

    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 2.02 Results of Operations and Financial Condition.</div>

      <div style="line-height: 1.25">&#160;</div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On May 9, 2025, Entera Bio Ltd., a company organized under the laws of the State of Israel (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or the &#8220;Company&#8221;),
        issued a press release announcing its financial results for the three months ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 2.02.</div>

      <div style="line-height: 1.25">&#160;</div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 7.01 Regulation FD Disclosure.</div>

      <div style="line-height: 1.25">&#160;</div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The information contained in Item 2.02 of this Current Report on Form 8-K is incorporated by reference in this Item 7.01.</div>

      <div style="line-height: 1.25">&#160;</div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The information contained in this Current Report on Form 8-K, including in Exhibit 99.1 attached hereto, is &#8220;furnished&#8221; and not
        &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference in another filing under the
        Exchange Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference.</div>

      <div style="line-height: 1.25">&#160;</div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 9.01 Financial Statements and Exhibits.</div>

      <div style="line-height: 1.25">&#160;</div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d) Exhibits.</div>

      <div style="line-height: 1.25;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 8.66%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit</div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Number</div>
            </td>

    <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td style="width: 90%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div>
            </td>

  </tr>

  <tr>

    <td style="width: 8.66%; vertical-align: bottom;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit_99-1.htm">99.1</a></div>
            </td>

    <td style="width: 1%; vertical-align: bottom;"><br/>
            </td>

    <td style="width: 90%; vertical-align: bottom;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit_99-1.htm">Press Release dated
                  May 9, 2025 announcing the Company&#8217;s financial results and business updates<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for the three months ended March 31, 2025.</span></a></div>
            </td>

  </tr>

  <tr>

    <td style="width: 8.66%; vertical-align: bottom;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104</div>
            </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 90%; vertical-align: bottom;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
            </td>

  </tr>


</table>
      <div style="line-height: 1.25;"><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      </div>

      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

      <div style="line-height: 1.25">&#160;</div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
        behalf by the undersigned thereunto duly authorized.</div>

      <div style="line-height: 1.25;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: bottom;">&#160;</td>

    <td style="vertical-align: bottom; width: 47%;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ENTERA BIO LTD.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: middle;">&#160;</td>

    <td style="width: 3%; vertical-align: bottom;">&#160;</td>

    <td style="width: 47%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: bottom;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date: May 9, 2025</div>
            </td>

    <td style="width: 3%; vertical-align: bottom;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
            </td>

    <td style="width: 47%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/&#160;Miranda Toledano</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: bottom;">&#160;</td>

    <td style="width: 3%; vertical-align: bottom;">&#160;</td>

    <td style="width: 47%; vertical-align: bottom;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name: Miranda Toledano</div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title: Chief Executive Officer</div>
            </td>

  </tr>


</table>
      <div><br/></div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

    </div>

  </div>

</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="font-weight: bold; text-align: right;"><u>Exhibit 99.1</u><u><br>
        </u></div>
    <div> <br>
    </div>
    <div>
      <div style="text-align: justify; line-height: 1.25;"><img width="136" height="100" src="image00001.jpg"></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Entera Bio Announces First Quarter 2025 Financial Results and Business Updates</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">JERUSALEM, May 9th 2025 &#8211;Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement
        therapies, today reported financial results and key business updates for the quarter ended March 31, 2025.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;During Q1 2025, Entera continued to generate intrinsic value with progress across our programs while significantly extending our cash
        runway into late 2026 via direct investment from marquis investors and our strategic partner, OPKO Health Inc. (&#8220;OPKO&#8221;). EB613 early mechanistic effects on both trabecular and cortical bone compartments data using 3D-Shaper software analysis was
        selected for oral presentation out of 1,680 abstracts submitted to the 2025 World Congress on Osteoporosis, Osteoarthritis and&#160;Musculoskeletal Diseases Congress. Subsequent EB613 abstracts have been submitted to both the 2025 American Society for
        Bone Mineral Research (ASBMR) and the North American Menopause Society (NAMS) conferences. Pre-IND activities for our Next Gen EB613 tablet candidate are in final stages, with plans to initiate a Phase 1 study in H2 2025. Via the execution of our
        recent license agreement with OPKO, we are fully funded to co-develop Oral OPK-88006 (the first dual acting GLP1/Glucagon single tablet for metabolic diseases) through SAD/MAD Phase 1 studies while retaining a 40% stake in the economics of this
        important asset. An abstract for Oral OPK-88006 has been submitted to ENDO2025. Finally, we are judiciously strengthening our core team with important appointments including Ms. Leslie Gautam, as Chief Business Officer and Ms. Cherin Smith as Head
        of Clinical Operations, both of whom have extensive experience in strategic and operational execution in women-centric conditions&#8221; said Miranda Toledano, Chief Executive Officer of Entera,&#8221;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;&#8220;We continue to optimize and prepare to initiate our proposed pivotal program for EB613, the first and only oral anabolic &#8220;bone
        building&#8221; tablet treatment under clinical investigation in postmenopausal women with osteoporosis. The earlier the age at which menopause occurs the greater the risk of long-term impact on bone and heart health. EB613 is specifically intended to
        provide an oral anabolic treatment in tablet format earlier in an osteoporosis patient&#8217;s journey to increase skeletal mass and reduce the risk of fracture. EB613 comprises the first 34 N-terminal amino acid sequence of the human parathyroid
        hormone, PTH(1-34) or teriparatide, which is a validated standard of care and only available as a daily subcutaneous injection. The morbidity and mortality risk of osteoporosis fractures to women outpaces that of breast cancer, stroke and heart
        attack combined. In the U.S., there are over 54 million American women and men with at-risk bone health and osteoporosis. The statistics associated with osteoporosis are staggering: fracture rates are on the rise state by state, severe mortality
        (20% - 30% die within 12 months of fracture), catastrophic comorbidity (50% of fracture survivors unable to walk independently), a persistent treatment chasm (&lt;25% receive osteoporosis medication) and escalating and preventable pharmacoeconomic
        burden ($57 billion in Medicare). No new osteoporosis drug has been approved by U.S. Food and Drug Administration (FDA) since 2019 due to the ethical, size and duration challenges imposed by fracture-based studies. At the heart of this significant
        public health concern is the need for regulatory reform of the fracture endpoint currently required for approval of osteoporosis drugs by the FDA. The single most important predictor of osteoporotic fractures in postmenopausal women without a
        previous fracture is bone mineral density (BMD).&#160; The SABRE (Study to Advance Bone Mineral Density as a Regulatory Endpoint), initiative has amassed the strongest evidence to date substantiating that gains in total&#8209;hip BMD reliably predict
        fracture&#8209;risk reduction as a viable surrogate to fracture. This is analogous to prior initiatives that qualified LDL cholesterol as a surrogate to cardiovascular outcomes and HBA1C as a surrogate to diabetes complications. In March&#8239;2024 the FDA
        Biomarker Division indicated to the SABRE group that a decision may be issued within 10&#8239;months. Recent presentations by SABRE at medical congresses indicate their continued optimism that a ruling by FDA on the qualification of BMD as a surrogate
        for fracture is expected in 2025. We strongly endorse the proposed BMD ruling and view it as crucial to reinvigorate much needed innovation and more treatment choices for patients and clinicians in this underserved disease. We will be taking
        additional steps to ensure the continuity of clinical development for EB613,&#8221; said Miranda Toledano, Chief Executive Officer of Entera.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Key Recent Highlights</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">EB613: First Oral PTH(1-34), teriparatide Anabolic Tablet Treatment Candidate for Women with Osteoporosis</div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z07f3c1b7579648b391eea841d69524cd" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On April 15 2025, our Chief Clinical Advisor Dr. Rachel B Wagman presented at the 2025 WCO-IOF-ESCEO Congress <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">"</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM
                  PHASE 2 STUDY.&#8221;&#160;</font>After 6 months of treatment, the findings showed increases with EB613 compared with placebo in a variety of indices, including integral volumetric BMD and trabecular volumetric BMD, cortical thickness, and cortical
                surface BMD. The evaluation showed a broad distribution of bone loss in the femur with placebo and a similarly broad distribution of bone gain in the femur with EB613. Mechanistically, the findings suggest that bone strengthening, and
                fracture resistance may occur rapidly with EB613. Furthermore, the data are consistent with those of published subcutaneous teriparatide at the 6-month time point. During the quarter, further abstracts have been submitted to ASBMR and NAMS
                2025 conferences</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z7c0e5118ba3e4a479105b6328e5f9db0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Next Gen EB613, which is being development with new generation of our N-TAB&#8482; platform, is finalizing pre-IND activities with a plan to enter the clinic in H2 2025. We
                plan to submit an abstract on Next Gen EB613 to a major medical conference in 2025</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">First GLP-1/Glucagon Agonist (Oxyntomodulin) Peptide Tablet Candidate for Obesity</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z9d383b11c37949f8828039db3112008d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In March 2025, we entered into a collaboration and license agreement with OPKO relating to the preclinical and clinical development of the Oral OXM program. Under
                  the terms of the agreement, OPKO and Entera will hold 60% and 40% pro-rata ownership interests, respectively, in the program and be responsible for 60% and 40% of the program&#8217;s development costs, respectively. We expect to file an
                  Investigational New Drug application with the FDA later this year or early in 2026</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z77be073dc0654ae1ab0bb82288e44da4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the quarter, we submitted an abstract for Oral OPK-88006 to ENDO2025</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">First GLP-2 Peptide Tablets for Short Bowel Syndrome</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z5166650ee1054e2baa144b9e1a668b05" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Given the challenging compliance rates attributed to injectable GLP-2 therapy and heterogeneity of short bowel syndrome (SBS) patients, we believe a daily tablet
                  format may address a significant unmet need in treating and titrating SBS patients more effectively than injectable alternatives. OPKO and Entera are determining next steps for this program. We plan to submit abstracts to a major clinical
                  conference with PK/PD of the single daily tablet of GLP-2 in late 2025</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Strong Additions to Entera Core Team</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" id="z0349ab1a54aa464a8f262bdd8535983d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In March 2025, Cherin Smith joined Entera as EVP, Head of Clinical Operations. Cherin is an accomplished leader with more than 20 years of experience in global
                  clinical operations leadership, project management, and vendor management. With more than a decade of strategic experience in women&#8217;s health, Cherin has a broad background in various therapeutic areas,&#160;including osteoporosis, metabolic
                  and rare diseases, and cardiovascular and CNS disorders. &#160;Cherin led the successful execution of 11 Phase 3 trials with BMD endpoints,&#160;including registrational Phase 3 programs for Orilissa&#174;, Myfembree&#174;, and Veozah&#174;,&#160;and has contributed
                  to NDA submissions. Cherin holds a Bachelor&#160;of Science, Psychobiology degree from the University of California, Los Angeles (UCLA) and is a certified Project Management Professional.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zf4f309402e2b48d3a8bd8af92886b11a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On May 8<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>, 2025, Leslie Gautam joined Entera as Chief Business Officer. Leslie has extensive strategic advisory experience across biopharma, with
                  transaction experience in both clinical and commercial stage companies with a particular focus on women&#8217;s health and supportive care. Most recently, Leslie was Co-Founder CEO of an early stage women's health company that provided care
                  delivery and innovation for patients with hyperemesis gravidarum. Prior to this role, Leslie held senior positions in the healthcare investment banking team&#160;at Stifel and Houlihan Lokey. Previously, she served as part of the business
                  development teams at Purdue Pharma and Noven Pharmaceuticals and was an Institutional Investor ranked equity research analyst for UBS covering the pharmaceutical sector. Leslie started her career in the healthcare investment banking group
                  of BMO Capital Markets. Leslie holds a B.S. in Psychobiology and Computer Programming from UCLA and an MBA in Finance from Columbia Business School.&#160;</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;I&#8217;m honored to join&#8239;Entera at such a pivotal moment for women&#8217;s health.&#8239;With an outstanding team and a pipeline designed to address
        long&#8209;overlooked conditions, we have an opportunity to turn scientific breakthroughs into meaningful, everyday impact for millions of patients. I&#8217;m excited to help accelerate that mission,&#8221; said Leslie Gautam, Chief Business Officer of Entera.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Financial Results for the Quarter Ended March 31, 2025</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As of March 31,2025, Entera had cash and cash equivalents and restricted cash of $20.6 million, of which $8 million has been
          designated to fund the collaboration activity with OPKO. The cash is expected to be sufficient to support the Company&#8217;s operations through the<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</font>middle of the third
          quarter of 2026.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" id="z09fc22cdd6444e168ec259695e30c598" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Research and development expenses for the three months ended March 31, 2025 were $1.1 million, as compared to $0.7 million for the three months ended March 31, 2024.
                The increase of $0.4 million was primarily due to an increase of $0.2 million in other consulting fees, including regulatory required in connection with the optimization processes related to the preparation of the EB613 phase 3 program,
                $0.1 million in connection with our internal programs and collaboration with OPKO and $0.1 million in share-based compensation.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zefdec66b4fb24e748541b713d178966e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">General and administrative expenses for the three months ended March 31, 2025 were $1.4 million, as compared to $1.3 million for the three months ended March 31,
                  2024. The increase of $0.1 million was mainly attributable to an increase in IP costs and legal fees related to the execution of our collaboration agreement with OPKO and other potential strategic agreements.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z254fe00be3b046f596cdc7dfdada2ee7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating expenses for the three Months ended March 31, 2025 were $2<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</font>6 million,
                  as compared to $2.1 million for the three Months ended March 31, 2024.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net loss was $2.6 million, or $0.06 per ordinary share (basic and diluted), for the three months ended March 31, 2025, as compared
          to 2.0 million, or $0.05 per ordinary share (basic and diluted), for the three months ended March 31, 2024.</div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">About Entera Bio</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet
          medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N-Tab&#8482;) and its pipeline of first-in-class oral peptide programs targeting
          PTH(1-34), GLP-1 and GLP-2. The Company&#8217;s most advanced product candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily&#160;tablet treatment for post-menopausal women with low BMD and
          high-risk osteoporosis. A placebo controlled, dose ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is preparing to initiate a Phase 3 registrational study for EB613
          pursuant to the FDA&#8217;s qualification of a quantitative BMD endpoint. The EB612 program is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral
          oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel
          syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">www.enterabio.com</font> or follow us on <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>LinkedIn</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Twitter</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Facebook</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Instagram</u></font>.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Contact:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Entera Bio:</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ms. Miranda Toledano</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Chief Executive Officer</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Entera Bio</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Email: <u>miranda@enterabio.com</u></font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Cautionary Statement Regarding Forward Looking Statements</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Various statements in this presentation are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation
        Reform Act of 1995. All statements (other than statements of historical facts) in this presentation regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward-looking
        statements. Words such as, but not limited to, &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;design,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;likely,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; and &#8220;would,&#8221;
        or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.
        Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Important factors that could cause actual results to differ materially from those reflected in Entera&#8217;s forward-looking statements
        include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA&#8217;s interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned
        preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss
        of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be contractually obligated to provide; overall regulatory timelines; the
        size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera&#8217;s product candidates; Entera&#8217;s reliance on third parties to conduct its clinical trials; Entera&#8217;s ability to establish and
        maintain development and commercialization collaborations; Entera&#8217;s operation as a development stage company with limited operating history; Entera&#8217;s competitive position with respect to other products on the market or in development for the
        treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories it pursues; Entera&#8217;s ability to continue as a going concern absent access to sources of liquidity; Entera&#8217;s ability to
        obtain and maintain regulatory approval for any of its product candidates; Entera&#8217;s ability to comply with Nasdaq&#8217;s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United
        States; Entera&#8217;s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the &#8220;Cautionary Statement Regarding Forward-Looking Statements,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s
        Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections of Entera&#8217;s most recent Annual Report on Form 10-K filed with the SEC, as well as Entera&#8217;s subsequently filed Quarterly Reports on Form 10-Q and Current Reports on
        Form 8-K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance
        can be given that the outcomes stated or implied in such forward-looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward-looking statements Entera makes in this presentation. The information in this
        presentation is provided only as of the date of this presentation, and Entera undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except to the
        extent required by law.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 88.2%; vertical-align: middle;" colspan="4">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ENTERA BIO LTD.</div>
              </td>
            </tr>
            <tr>
              <td style="width: 88.2%; vertical-align: middle;" colspan="4">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CONSOLIDATED BALANCE SHEETS</div>
              </td>
            </tr>
            <tr>
              <td style="width: 88.2%; vertical-align: middle;" colspan="4">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(U.S. dollars in thousands)</div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z28b94e783a674043acfc38ddc610bbb8" class="cfttable">

            <tr>
              <td valign="bottom" style="vertical-align: middle;">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="vertical-align: middle;" colspan="2">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">March 31,</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="vertical-align: middle;" colspan="2">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="vertical-align: middle; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> 2025</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="vertical-align: middle; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2024</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="vertical-align: middle; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Unaudited)</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="vertical-align: middle; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Audited)</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: middle;">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="vertical-align: middle;" colspan="6">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cash and cash equivalents</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12,573</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,660</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: middle; width: 76%;">
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Accounts receivable and other current assets</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">645</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">312</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Restricted cash</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,000</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: middle; width: 76%;">
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Property and equipment, net</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">57</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">57</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: middle; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other assets</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">325</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">361</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: middle; width: 76%; padding-bottom: 4px;">
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total assets</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21,600</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,390</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: middle; width: 76%;">
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Accounts payable and other current liabilities</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,623</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,176</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total non-current liabilities</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">598</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">134</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: middle; width: 76%;">
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total liabilities</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,221</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,310</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total shareholders' equity</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">19,379</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,080</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: middle; width: 76%;">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: middle; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total liabilities and shareholders' equity</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21,600</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,390</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">ENTERA BIO LTD.</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
        </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">CONSOLIDATED STATEMENTS OF OPERATIONS</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
        </font>(U.S. dollars in thousands, except share and per share data)</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Unaudited)</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z07825cabd00249ccb146b774942e1b08" class="cfttable">

          <tr>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="line-height: 1.25;">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-indent: 1pt;">Three Months Ended</div>
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-indent: 1pt;">March 31,</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="line-height: 1.25;">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-indent: 1pt;"> 2025</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="line-height: 1.25;">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-indent: 1pt;">2024</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">REVENUES</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">42</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">COST OF REVENUES</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">42</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">GROSS PROFIT</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">OPERATING EXPENSES:</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;&#160;&#160;&#160;</font>Research and
                development</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,123</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">735</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;General and administrative</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,440</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,327</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">TOTAL OPERATING EXPENSES</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,563</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,062</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">OPERATING LOSS</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,563</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,062</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">FINANCIAL INCOME, NET</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(45</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
              </div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">NET LOSS</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,567</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,017</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">LOSS PER SHARE BASIC AND DILUTED</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.06</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.05</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">

              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">43,377,391</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">

              <div style="line-height: 1.25;">

                <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">36,735,429</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>entx-20250509.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.2.1.5287 Broadridge-->
<xs:schema targetNamespace="http://enterabio.com/20250509" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:entx="http://enterabio.com/20250509" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt-types="http://fasb.org/srt-types/2024">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="entx-20250509_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="entx-20250509_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="entx-20250509_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://enterabio.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
  <xs:element name="WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" id="entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OrdinarySharesParValueOfNIS00000769Member" id="entx_OrdinarySharesParValueOfNIS00000769Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>entx-20250509_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.2.1.5287 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://enterabio.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="entx-20250509.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://enterabio.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentType" xlink:title="definition: EntityListingsLineItems to DocumentType" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="AmendmentFlag" xlink:title="definition: EntityListingsLineItems to AmendmentFlag" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentPeriodEndDate" xlink:title="definition: EntityListingsLineItems to DocumentPeriodEndDate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalYearFocus" xlink:title="definition: EntityListingsLineItems to DocumentFiscalYearFocus" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalPeriodFocus" xlink:title="definition: EntityListingsLineItems to DocumentFiscalPeriodFocus" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityFileNumber" xlink:title="definition: EntityListingsLineItems to EntityFileNumber" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityRegistrantName" xlink:title="definition: EntityListingsLineItems to EntityRegistrantName" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityCentralIndexKey" xlink:title="definition: EntityListingsLineItems to EntityCentralIndexKey" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityIncorporationStateCountryCode" xlink:title="definition: EntityListingsLineItems to EntityIncorporationStateCountryCode" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityTaxIdentificationNumber" xlink:title="definition: EntityListingsLineItems to EntityTaxIdentificationNumber" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine1" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine1" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine2" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine2" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine3" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine3" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCityOrTown" xlink:title="definition: EntityListingsLineItems to EntityAddressCityOrTown" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressStateOrProvince" xlink:title="definition: EntityListingsLineItems to EntityAddressStateOrProvince" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCountry" xlink:title="definition: EntityListingsLineItems to EntityAddressCountry" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressPostalZipCode" xlink:title="definition: EntityListingsLineItems to EntityAddressPostalZipCode" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="CityAreaCode" xlink:title="definition: EntityListingsLineItems to CityAreaCode" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="LocalPhoneNumber" xlink:title="definition: EntityListingsLineItems to LocalPhoneNumber" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="Security12bTitle" xlink:title="definition: EntityListingsLineItems to Security12bTitle" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="TradingSymbol" xlink:title="definition: EntityListingsLineItems to TradingSymbol" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="NoTradingSymbolFlag" xlink:title="definition: EntityListingsLineItems to NoTradingSymbolFlag" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="SecurityExchangeName" xlink:title="definition: EntityListingsLineItems to SecurityExchangeName" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityEmergingGrowthCompany" xlink:title="definition: EntityListingsLineItems to EntityEmergingGrowthCompany" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="WrittenCommunications" xlink:title="definition: EntityListingsLineItems to WrittenCommunications" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="SolicitingMaterial" xlink:title="definition: EntityListingsLineItems to SolicitingMaterial" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementTenderOffer" xlink:title="definition: EntityListingsLineItems to PreCommencementTenderOffer" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="definition: EntityListingsLineItems to PreCommencementIssuerTenderOffer" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EntityListingsLineItems" xlink:to="EntityListingsTable" xlink:title="definition: EntityListingsLineItems to EntityListingsTable" order="29.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="EntityListingsTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: EntityListingsTable to StatementClassOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="entx-20250509.xsd#entx_OrdinarySharesParValueOfNIS00000769Member" xlink:label="OrdinarySharesParValueOfNIS00000769Member" xlink:title="OrdinarySharesParValueOfNIS00000769Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="OrdinarySharesParValueOfNIS00000769Member" xlink:title="definition: ClassOfStockDomain to OrdinarySharesParValueOfNIS00000769Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="entx-20250509.xsd#entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" xlink:label="WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" xlink:title="WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" xlink:title="definition: ClassOfStockDomain to WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" order="2.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>entx-20250509_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.2.1.5287 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockDomain" xml:lang="en-US" id="us-gaap_ClassOfStockDomain">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="label: ClassOfStockDomain to us-gaap_ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementClassOfStockAxis" xml:lang="en-US" id="us-gaap_StatementClassOfStockAxis">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="label: StatementClassOfStockAxis to us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:label xlink:type="resource" xlink:label="dei_EntityListingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityListingsTable" xml:lang="en-US" id="dei_EntityListingsTable">Entity Listings [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityListingsTable" xlink:to="dei_EntityListingsTable" xlink:title="label: EntityListingsTable to dei_EntityListingsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:label xlink:type="resource" xlink:label="dei_EntityListingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityListingsLineItems" xml:lang="en-US" id="dei_EntityListingsLineItems">Entity Listings [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityListingsLineItems" xlink:to="dei_EntityListingsLineItems" xlink:title="label: EntityListingsLineItems to dei_EntityListingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
    <link:loc xlink:type="locator" xlink:href="entx-20250509.xsd#entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" xlink:label="WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" xlink:title="WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" />
    <link:label xlink:type="resource" xlink:label="entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember_lbl1" xml:lang="en-US" id="entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember_lbl1">Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary Share [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" xlink:to="entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember_lbl1" xlink:title="label: WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember to entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="entx-20250509.xsd#entx_OrdinarySharesParValueOfNIS00000769Member" xlink:label="OrdinarySharesParValueOfNIS00000769Member" xlink:title="OrdinarySharesParValueOfNIS00000769Member" />
    <link:label xlink:type="resource" xlink:label="entx_OrdinarySharesParValueOfNIS00000769Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="entx_OrdinarySharesParValueOfNIS00000769Member_lbl1" xml:lang="en-US" id="entx_OrdinarySharesParValueOfNIS00000769Member_lbl1">Ordinary Shares, par value of NIS 0.0000769 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrdinarySharesParValueOfNIS00000769Member" xlink:to="entx_OrdinarySharesParValueOfNIS00000769Member_lbl1" xlink:title="label: OrdinarySharesParValueOfNIS00000769Member to entx_OrdinarySharesParValueOfNIS00000769Member_lbl1" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>entx-20250509_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.2.1.5287 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://enterabio.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="entx-20250509.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://enterabio.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="entx-20250509.xsd#entx_OrdinarySharesParValueOfNIS00000769Member" xlink:label="OrdinarySharesParValueOfNIS00000769Member" xlink:title="OrdinarySharesParValueOfNIS00000769Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="OrdinarySharesParValueOfNIS00000769Member" xlink:title="presentation: ClassOfStockDomain to OrdinarySharesParValueOfNIS00000769Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="entx-20250509.xsd#entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" xlink:label="WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" xlink:title="WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" xlink:title="presentation: ClassOfStockDomain to WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: EntityListingsTable to StatementClassOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentType" xlink:title="presentation: EntityListingsLineItems to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="AmendmentFlag" xlink:title="presentation: EntityListingsLineItems to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: EntityListingsLineItems to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: EntityListingsLineItems to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: EntityListingsLineItems to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityFileNumber" xlink:title="presentation: EntityListingsLineItems to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityRegistrantName" xlink:title="presentation: EntityListingsLineItems to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityCentralIndexKey" xlink:title="presentation: EntityListingsLineItems to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: EntityListingsLineItems to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: EntityListingsLineItems to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: EntityListingsLineItems to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: EntityListingsLineItems to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCountry" xlink:title="presentation: EntityListingsLineItems to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: EntityListingsLineItems to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="CityAreaCode" xlink:title="presentation: EntityListingsLineItems to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="LocalPhoneNumber" xlink:title="presentation: EntityListingsLineItems to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="Security12bTitle" xlink:title="presentation: EntityListingsLineItems to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="TradingSymbol" xlink:title="presentation: EntityListingsLineItems to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: EntityListingsLineItems to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="SecurityExchangeName" xlink:title="presentation: EntityListingsLineItems to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: EntityListingsLineItems to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="WrittenCommunications" xlink:title="presentation: EntityListingsLineItems to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="SolicitingMaterial" xlink:title="presentation: EntityListingsLineItems to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: EntityListingsLineItems to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: EntityListingsLineItems to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsTable" xlink:to="EntityListingsLineItems" xlink:title="presentation: EntityListingsTable to EntityListingsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityListingsTable" xlink:title="presentation: CoverAbstract to EntityListingsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ J "H  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ": -8# 2(  A$! Q$!_\0
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M_P!*0GL/O>E?B9^U)_P5DE?XSP?L7_\ !/'P-IO[5'[7.K75QINMZPMS</\
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MS))S+]ZX_GG],?RIN<<#COT)[^W_ .JOGL9Q?GV+A.C3Q5#*\+44HSP60X#
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M_1^+=%\*>%/!E]X?TJ>6]TN;X0>"X=EWJ/B2PA^T-KD3Q@MY5M>3&.W/U?\
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M?\%F/C/H?P<T,>+?B!/^T#X9^#?P[\/""WO;&XU[X1V?A_X;[;R.Y!LTT?\
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MG.,910'(S2T45^R'V(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
J%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 09, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  09,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Entera Bio Ltd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001638097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">KIRYAT HADASSAH, MINRAV BUILDING<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">FIFTH FLOOR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">JERUSALEM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">9112002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">2-532-7151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=entx_OrdinarySharesParValueOfNIS00000769Member', window );">Ordinary Shares, par value of NIS 0.0000769 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, par value of NIS 0.0000769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember', window );">Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENTXW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=entx_OrdinarySharesParValueOfNIS00000769Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=entx_OrdinarySharesParValueOfNIS00000769Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *R J5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( *R J5HI1UR[[@   "L"   1
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MM5II ,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A
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M              "  > !  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *R J5HD'INBK0   /@!   :
M          "  :D2  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( *R J5IED'F2&0$  ,\#   3              "  8X3  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  -@4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="zk2533149.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enterabio.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>entx-20250509.xsd</File>
    <File>entx-20250509_def.xml</File>
    <File>entx-20250509_lab.xml</File>
    <File>entx-20250509_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="zk2533149.htm">zk2533149.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "zk2533149.htm": {
   "nsprefix": "entx",
   "nsuri": "http://enterabio.com/20250509",
   "dts": {
    "schema": {
     "local": [
      "entx-20250509.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "entx-20250509_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "entx-20250509_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "entx-20250509_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "zk2533149.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 9,
    "http://xbrl.sec.gov/dei/2024": 9
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 35,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 26
   },
   "report": {
    "R1": {
     "role": "http://enterabio.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20250509to20250509",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2533149.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250509to20250509",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2533149.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "entx_OrdinarySharesParValueOfNIS00000769Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enterabio.com/20250509",
     "localname": "OrdinarySharesParValueOfNIS00000769Member",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary Shares, par value of NIS 0.0000769 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enterabio.com/20250509",
     "localname": "WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary Share [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001178913-25-001673-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-25-001673-xbrl.zip
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M6Q1/(7:TZI))94+I!I+*H*UR,VZ#_&B@EUG=#[TAJNH 3A\]4KG>@D5NK:!
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MBX,*&]EKG;=T>7=WD5+^E/G!RV#A\^=OXG^Z[/:+7^)_H'S\'U!+ P04
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M-S!3Z0_8QQ&9XB?UT: "E,X2^ZB+,40NM</LL!].FL'F'<Q4\LGJ>43&!/]
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M=.Q;.(?)&HA&/7DG;0<!AKP(E"[X:X;<%.A;N@HX)8#B3U!+ (L8-R:>;]C
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M<'  <<0;<>IY%JWA!-_K6D"7-HE0''WW]*2[AXJ1B;IKK0/:DXK5; 7@ATW
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M/3%[XDHG/&FK)F_+] V%?LJ7L/&>",+G<<Z.U6@WC%K-;!QTFIUANUUO5QO
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MH\O/HO?OJ][EH#=XOPK)O4E\98,XQO=7Z&QL?4Z!)066K)OU;HE-]?HYM7P
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MI:]BQF-]+V04>LDCGV>A9_F[B=/?X]\^O#,\:T:_C,.) [_\?U!+ P04
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M>2-?\-;#+DK/3^ ]N8X(+RH![XFC/\!Y2FDHW:L%XM]8Z._4<VT%Q05%Y62
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MJ!>3:"+">$@D,.\$:^1+XQ,D2]P_3^,QI^\8=!<X5;$,('.IRN 1YX*^C\(
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M*#0$V681(^(*XCB1@:Y)RB04C*1(MA)7;H<R^)7?_"2FKY!OT6,T%2A<A8"
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MK\7+K\=GHZCU'U!+ 0(4 Q0    ( *R J5IQ0V)1"@0  -T2   1
M      "  0    !E;G1X+3(P,C4P-3 Y+GAS9%!+ 0(4 Q0    ( *R J5JV
M6WIL)@<  $Y&   5              "  3D$  !E;G1X+3(P,C4P-3 Y7V1E
M9BYX;6Q02P$"% ,4    " "L@*E:I8%OYI<*   =:P  %0
M@ &2"P  96YT>"TR,#(U,#4P.5]L86(N>&UL4$L! A0#%     @ K("I6AH/
MX.$N!P  V4X  !4              ( !7!8  &5N='@M,C R-3 U,#E?<')E
M+GAM;%!+ 0(4 Q0    ( *R J5KQ:P .3"H  *UV 0 0              "
M ;T=  !E>&AI8FET7SDY+3$N:'1M4$L! A0#%     @ K("I6AVX'<P>%
MN8,   T              ( !-T@  'IK,C4S,S$T.2YH=&U02P4&      8
,!@"! 0  @%P

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>zk2533149_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:entx="http://enterabio.com/20250509"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="entx-20250509.xsd" xlink:type="simple"/>
    <context id="c20250509to20250509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <startDate>2025-05-09</startDate>
            <endDate>2025-05-09</endDate>
        </period>
    </context>
    <context id="c20250509to20250509_StatementClassOfStockAxis_OrdinarySharesParValueOfNIS00000769Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">entx:OrdinarySharesParValueOfNIS00000769Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-09</startDate>
            <endDate>2025-05-09</endDate>
        </period>
    </context>
    <context id="c20250509to20250509_StatementClassOfStockAxis_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">entx:WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-09</startDate>
            <endDate>2025-05-09</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20250509to20250509"
      id="Fact_e3793fd0246149fc909fd1fcfc95fa89">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20250509to20250509"
      id="Fact_2783e5c0c3ef4b5c98066465eeb39ec2">0001638097</dei:EntityCentralIndexKey>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20250509to20250509"
      id="Fact_1fc99da374d94b47827b63bc4df1ea69">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:CityAreaCode
      contextRef="c20250509to20250509"
      id="Fact_845dc47bf7764f37ae6b3ec21fdb1f1c">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20250509to20250509"
      id="Fact_5b00f5ad8e2a42019f08b2e5b15a63bf">2-532-7151</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="c20250509to20250509_StatementClassOfStockAxis_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember"
      id="Fact_33337dadb56448e6803d820203d94d6e">Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20250509to20250509_StatementClassOfStockAxis_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember"
      id="Fact_a700b67d61a142d989acfd1e03ccdf9c">ENTXW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20250509to20250509_StatementClassOfStockAxis_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember"
      id="Fact_19ac239564e543ae8bdeb253ce77e391">NASDAQ</dei:SecurityExchangeName>
    <dei:SecurityExchangeName
      contextRef="c20250509to20250509_StatementClassOfStockAxis_OrdinarySharesParValueOfNIS00000769Member"
      id="Fact_90e9abc973f6425ea56ebe4d147111d6">NASDAQ</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="c20250509to20250509"
      id="Fact_854b9d1282cb4016850c835312cb7428">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20250509to20250509"
      id="Fact_24f7136a7a434d1c8823a066ae74f5f0">2025-05-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20250509to20250509"
      id="Fact_dc6cd0bdce1a4d91ac30bf2333ad64ce">Entera Bio Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20250509to20250509"
      id="Fact_5ccef13b5de64531b55131310f990d6d">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20250509to20250509"
      id="Fact_8531f7f8deb54d378365f039779ae88e">001-38556</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20250509to20250509"
      id="Fact_53e7134a8dee464d8f80218269c94f83">KIRYAT HADASSAH, MINRAV BUILDING</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20250509to20250509"
      id="Fact_2921a3eff99c4dd5bff84c01cafc4be3">FIFTH FLOOR</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20250509to20250509"
      id="Fact_c317e05c204f4a59a1e4dc8b1f3613c8">JERUSALEM</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="c20250509to20250509"
      id="Fact_5dfe71dfd21e4ab8aee3d679ab8f226a">IL</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="c20250509to20250509"
      id="Fact_70b738c460a04d3c9513ff7984b36624">9112002</dei:EntityAddressPostalZipCode>
    <dei:WrittenCommunications
      contextRef="c20250509to20250509"
      id="Fact_aedbad8e66824d61914f676dc82e5ccb">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20250509to20250509"
      id="Fact_76572359dc7d4cb7bad6d925fd113c86">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20250509to20250509"
      id="Fact_25c510ae2a4d49a890418808323caadb">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20250509to20250509"
      id="Fact_095cdde2305a4992902e14b13d9e8daf">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20250509to20250509_StatementClassOfStockAxis_OrdinarySharesParValueOfNIS00000769Member"
      id="Fact_ed98f41c93304b78938876a12e4df08c">Ordinary Shares, par value of NIS 0.0000769</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20250509to20250509_StatementClassOfStockAxis_OrdinarySharesParValueOfNIS00000769Member"
      id="Fact_8f25ca98f88f4f82bc488b6b84f08e53">ENTX</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20250509to20250509"
      id="Fact_93ab7cbcbd0b4c55bd07e713e802587e">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
